PFE - Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? | Benzinga
Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic.
The Tema Cardiovascular and Metabolics ETF (NASDAQ:HRST) launches on the NASDAQ exchange on Tuesday and will look to cash in on the massive popularity of a new breed of drugs called semaglutides, which include Novo Norkdisk‘s (NYSE:NVO) Ozempic and Wegovy and Eli Lilly‘s (NYSE:LLY) Mounjaro.
“Cardiovascular and metabolic diseases are closely intertwined, combining a larger, well-established area of healthcare with a burgeoning new biopharma sector: obesity,” said Maurits Pot, co-founder and CEO of TEMA.
“This area has recently announced and launched several breakthrough therapies underscoring the pace of innovation that we believe will transform patient lives and outcomes.”
Also Read: ...